Managerial Accounting
Group 22
Vijay Ganapathy
1122
Bhargav Hazarika
1215
Thanmai Reguri
1167
Rishabh Srivastava 1145
About Company
Name of the company: Dr. Reddy's
Industry: Pharmaceuticals
CEO:: Erez Israeli
Major Brands
Financial Highlights
Q4 FY21
Rs. Cr
QoQ Gr%
YoY Gr%
FY21
YoY Gr%
Revenues
4,728
-4%
7%
18,972
9%
EBITDA
1,133
-4%
13%
4,748
2%
PBT
807
184%
13%
2,832
57%
PAT
554
2695%
-28%
1,915
-2%
Highest ever
Revenues and EBITDA
P&L Metrics
60%
51.5%
R&D Expenses
SG&A Expenses
Gross Margin
51.5%
53.8%
1,439
1,500
1,218
40%
1,000
20%
500
1,428
500
419
411
409
9.5%
8.3%
400
300
200
0%
Q3
FY 2020
Q4
FY 2020
60%
53.8%
Q4
FY 2021
54.3%
0
27.5%
29.2%
Q3
FY 2020
Q4
FY 2020
6,000
30.2%
5,013
Q4
FY 2021
5,456
100
0
Q4
FY 2020
Q3
FY 2020
2,000
1,541
1,654
8.8%
8.7%
1,500
4,000
40%
1,000
2,000
20%
28.7%
0
0%
FY20
FY 21
FY20
28.8%
500
0
FY 21
FY20
FY 21
8.7%
Q4
FY 2021
India – YOY growth
REVENUES
Rs. 845 cr
QoQ GR
-12%
YoY DC
23%
Q4 FY21 & FY21 YoY revenue growth is primarily due to acquired
portfolio from Wockhardt and new products contribution
Q4 FY21 QoQ revenue decline due to reduction in Covid
portfolio sales & seasonality
IQVIA growth rates
FY21
Rs. 3,342 cr
YoY Gr
15%
Mar 2021
FTM
IPM
16.4%
8.5%
4.3%
Dr. Reddy's
17.6%
9.7%
3.1%
MQT
MAT
- Ranked 11th on MAT basis vs. 13th in Mar 2020
FTM: For the month
MAT: Moving annual total
MQT: Moving quarterly tota
eMERGING MARKETS
REVENUES
Rs. 845 cr
QoQ Gr
-8%
YoY DC
10%
Region
Q4 FY21
YoY Gr
QoQ Gr
FY21
404
3%
-10%
1582
-6%
CISR
96
7%
6%
743
15%
RoW
77
2.4%
-1%
1,184
25%
EM
396
10%
-5%
3509
7%
Russia
Russia
FY21
Rs. 3,509 cr
YoY Gr
7%
YoY Gr
• Growth impacted due to weakening Ruble.
• FY21 constant currency growth @ 1%
CISR
• YoY growth primarily driven by Kazak, Romania & Uzbek.
ROW
• YoY growth led by China, Vietnam, Myanmar & Jamaica.
Comparison with its peers
Dr.Reddy’s Ranbaxy
Cipla
Sun Pharma Aurobindo
Current Ratio(X)
2.4
0.62
3.79
1.45
1.83
Quick Ratio(X)
1.78
0.43
2.64
1.07
1.12
Debt to Equity(X)
0.07
5.46
0
0.26
0.25
Net Profit Margin(%)
16.37
(12.8)
17.75
16.71
19.67
Return on Equity(%)
12.87
0
12.38
8.54
19.54
GUESS???
Which vaccine Dr. Reddy's is helping in
distribution???
Key Priorities
Ensure
Covid portfolio
supplies including
Sputnik-V
uninterrupted
operations during
Achieve market
Build healthy
leading growth
pipeline of
across businesses
products
Covid19 times
Continue with the
Investment in
Execute Strategic
productivity
capabilities and
initiatives &
improvements
brands
moves
Thank You !1!